Top 20 global biopharmaceutical firms experience varied market capitalisation shifts in Q3 2023: GlobalData, Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com

Out of the top 20 companies, nine saw their market capitalisation surge by more than 10 per cent, with significant gains achieved by Amgen (22.1 per cent), Lilly (16.1 per cent), Regeneron Pharmaceuticals (14.9 per cent), Novo Nordisk (13.9 per cent), and AbbVie (13.1 per cent)., Out of the top 20 companies, nine saw their market capitalisation surge by more than 10 per cent, with significant gains achieved by Amgen (22.1 per cent), Lilly (16.1 per cent), Regeneron Pharmaceuticals (14.9 per cent), Novo Nordisk (13.9 per cent), and AbbVie (13.1 per cent)., , Read More